Despacilina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Despacilina

What is Despacilina? Defining the Core Antibiotic Entity

Property Description
Active Ingredient Benzylpenicillin (Penicillin G)
Form Powder for injection, Injectable suspension
Pharmacological Class beta-Lactam Antibiotic (Natural Penicillin)
General Purpose To eliminate penicillin-sensitive bacteria
Route Parenteral (Injection)

Despacilina is a prescription-only medication that functions as a highly targeted antibiotic used specifically to address bacterial infections. Its therapeutic action relies entirely on a single active ingredient, which is Benzylpenicillin, also internationally recognized as Penicillin G. This medication is classified within the foundational beta-lactam antibiotic family and is globally and clinically recognized for its efficacy against specific susceptible pathogens.

Composition, Origin, and Unique beta-Lactam Type

The core substance, Benzylpenicillin, is a historically significant natural penicillin originally derived from the Penicillium fungi. Despacilina is a single-entity product typically prepared as a powder for injection or an injectable suspension, differentiating it from oral penicillin formulations. The active compound is formulated into different salts—such as the highly water-soluble sodium salt or the poorly soluble benzathine salt—to control the speed at which the medicine is absorbed and released into the system. These diverse salt forms are necessary to ensure the drug can achieve effective therapeutic concentrations for various systemic uses, a fundamental pharmacological principle.

How Despacilina Works to Resolve Infection

Despacilina functions as a bactericidal antimicrobial, meaning it actively works to kill susceptible bacteria rather than merely halting their growth. It achieves this by interfering with a critical, protective structure of the bacterial cell: the cell wall. By inhibiting the biosynthesis of this cell wall, Despacilina causes the bacteria to become unstable and die, which is the necessary step toward clearing the infectious process caused by penicillin-sensitive pathogens. A typical, neutral use scenario involves its application in hospital settings to manage established severe infections caused by these susceptible organisms.

What side effects are possible with Despacilina?

Possible Side Effects and Safety Information

Despacilina (Benzylpenicillin/Penicillin G) has a specific profile of documented adverse reactions and safety characteristics defined in official regulatory documents. This information is classified by the system or organ affected and the estimated frequency of occurrence.


High-Level Adverse Reaction Classifications

The most frequently cited concern involves Immune System Disorders, primarily hypersensitivity reactions. These range from common skin effects, such as Urticaria (hives), to the rare but critical event of anaphylactic shock. Other common adverse effects include Gastrointestinal Disturbances, such as diarrhea, and injection site reactions (pain, inflammation), which are common given the parenteral route of administration.

Less commonly, the drug is associated with changes in the Blood and Lymphatic System, like Eosinophilia or Leukopenia. Rare, serious adverse reactions documented in regulatory labels include Acute Interstitial Nephritis (affecting the renal system) and Pseudomembranous Colitis.


Serious Safety Considerations

The potential for severe neurotoxicity is a primary safety concern, particularly the risk of seizures or convulsions. These events are dose-related and associated with very high systemic concentrations of the medicine. Due to this characteristic, patients with renal impairment are specifically noted as a population at increased risk of toxicity, as their reduced kidney function impairs the antibiotic's clearance. The medicine is strictly contraindicated in individuals with any known history of allergy to penicillin.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Despacilina (Benzylpenicillin/Penicillin G) emphasizes that overdose is a serious event primarily associated with Central Nervous System (CNS) toxicity.

Documented Overdose Manifestations

System Officially Documented Signs
Neurological Convulsive seizures, confusion, agitation, neuromuscular hyperirritability, jerking movements, coma, visual/auditory hallucinations.
Systemic Weakness, fast, slow, or irregular heartbeat.

Overdose typically occurs with massive doses or when the drug accumulates, such as in cases of impaired renal function. Regulator documents specifically highlight that patients with renal impairment face an increased risk of severe CNS toxicity and convulsions.

Required Emergency Actions

The official prescribing information mandates specific actions to seek urgent medical attention. Immediate medical help is required if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The documents specify that in such circumstances, contact emergency services (e.g., call 911) and the poison control helpline immediately. Management for overdose is limited to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known.

Therapeutic Uses of Despacilina

Despacilina (Benzylpenicillin/Penicillin G) is commonly used to help with serious infections caused by susceptible bacteria. It is applied in addressing conditions marked by significant physiological stress, which may assist with supporting the patient during difficult symptomatic episodes and easing the potential symptom load. Its applicability in serious conditions is considered relevant within therapeutic guidelines.

The medicine is relevant for easing conditions where infection has become generalized, such as septicemia, or is involving organ-specific functional stress, including the lining of the heart or the central nervous system (meningitis). It is also commonly used for deep-seated tissue conditions like osteomyelitis and in specific protocols for the long-term management of Syphilis and in situations involving the risk of recurrence of rheumatic fever. This approach is considered relevant for easing symptoms that interfere with functional stability, which may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Supports Management of Systemic Imbalance

Eligibility and Restrictions for Use

Who Can and Cannot Use Despacilina?

Eligibility for Despacilina (Benzylpenicillin/Penicillin G) is strictly defined by regulatory authorities based on a patient's hypersensitivity status, physiological function, and age.

Contraindications: Who Must Not Use

Despacilina is contraindicated in patients with a known history of hypersensitivity to any penicillin or a history of a severe immediate hypersensitivity reaction to other beta-lactam agents, such as cephalosporins. Local application to the skin, mucous membranes, or via aerosol is also prohibited.

Populations Requiring Caution or Restriction

Use is restricted or requires caution in several specific populations:

  • Organ Function Impairment: Patients with severe renal impairment require mandatory dosage reduction, as regulatory documents note delayed drug clearance. Caution is also necessary in patients with hepatic damage.
  • Comorbidities: Caution is required in individuals with a history of significant allergies, asthma, severe heart conditions (cardiopathies), or epilepsy.
  • Age and Clearance: The medicine is approved for use in adults, adolescents, children, and neonates. However, clearance is delayed in both neonates (premature infants) and the elderly due to reduced renal function.

Pregnancy and Lactation

Regulatory data generally indicate that Despacilina is not contraindicated during pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Despacilina Interactions with other medicines and products

Despacilina (Benzylpenicillin/Penicillin G) has documented interaction patterns based on its elimination pathway and specific pharmacodynamic effects. These interactions define certain restrictions and cautions according to official regulatory labeling.

Pharmacokinetic and Toxicity Interactions

Classification Interacting Agent Official Documented Outcome
Exposure Modification Probenecid Increases the plasma concentration and prolongs elimination by blocking renal tubular secretion of Despacilina.
Toxicity Risk Methotrexate Co-administration is not recommended due to reduced excretion of Methotrexate, officially leading to an increased risk of toxicity.

Pharmacodynamic and Procedural Restrictions

Interactions involving antagonism or chemical incompatibility are noted in regulatory information:

  • Antagonistic Drug Classes: Co-administration with bacteriostatic antibiotics, such as the tetracyclines, is officially not recommended. Regulatory sources state this combination may result in an antagonistic effect that interferes with Despacilina's bactericidal activity.
  • Anticoagulants: There is documented potential for Despacilina to increase the anticoagulant activities of medicines used to thin the blood.
  • Incompatibility Restriction: Despacilina must not be mixed with any other medications in the same syringe or infusion to avoid documented chemical or physical incompatibility.

Population-Specific Clearance

Patients with impaired renal function are subject to a key interaction-related caution. Reduced kidney function causes delayed elimination of Despacilina, leading to its accumulation and an elevated risk of neurotoxicity.

Mechanism of Action

Mechanism of Action: How Despacilina Works

Despacilina's mechanism is a bactericidal process that focuses exclusively on disrupting the structural integrity of susceptible bacteria, tracing the causal chain from molecular enzyme inactivation to cell death.


Irreversible Inactivation of Penicillin-Binding Proteins (PBPs)

Despacilina acts as an irreversible covalent inhibitor that permanently binds to and inactivates Penicillin-Binding Proteins (PBPs)—the bacterial enzymes essential for building the cell wall. This specific interaction immediately halts the crucial cross-linking step in peptidoglycan synthesis, the main structural component of the bacterial cell.


Collapse of Bacterial Osmotic Integrity

By preventing the formation of a stable, functional cell wall, the drug causes the pathogen to lose its ability to withstand the immense osmotic pressure exerted from within. This catastrophic structural failure leads to the rupture of the cell membrane and resulting cell lysis, which results in the degradation and elimination of the pathogen.


Constraints via Pathogen Defense Systems

The mechanism is functionally disabled if the bacteria produce the defense enzyme beta-lactamase (penicillinase), which hydrolyzes and neutralizes the drug before it can reach the PBP target. Furthermore, the drug is only effective against bacteria that are in a phase of active growth and replication, as the mechanism relies on the synthesis of new cell wall components.

Dosage and Administration Information

How to Use Despacilina

Despacilina, containing Benzylpenicillin (Penicillin G), is administered exclusively via parenteral routes due to its formulation as a powder for injection or an injectable suspension. The medicine is used either through Intravenous (IV) injection or infusion, or by Intramuscular (IM) injection, with the specific route determined by the salt form and the clinical scenario. The highly water-soluble sodium or potassium salts are typically administered intravenously for rapid systemic effect.

Administration frequency often involves divided daily doses given intermittently (e.g., every four to six hours) or as a continuous IV infusion to maintain consistent levels. The specific usage pattern for long-acting formulations, such as the Benzathine salt, involves deep IM injection only (never IV) and is often administered as a single dose or repeated weekly for conditions like Syphilis.

Dosing is calculated in International Units (IU), with standard adult regimens for severe infections ranging from 6 to 24 million units per day. The preparation of the powder requires reconstitution and dilution with a specified solvent before administration, and IV doses are typically given over a slow infusion lasting 30 to 60 minutes. Dose adjustment is mandatory for patients with renal impairment to prevent accumulation, which is a critical consideration in clinical practice.

Recent Clinical Evidence

The research evidence for Despacilina (Benzylpenicillin G) is established through both older historical data and modern controlled studies, primarily examining its approved uses in bacterial infections.

For the treatment of Syphilis, the evidence base includes Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitor serological outcomes, which track changes in blood markers over time, as well as the potential for microbiological failure. While a significant portion of the evidence is derived from established historical practice, the research is frequently used as a comparator in trials investigating newer treatments.

In the prevention of Rheumatic Fever recurrence, the evidence relies on long-term historical cohort studies that monitor the rate of recurring episodes. Findings describe the medicine's use as a component in global health protocols. Reviewers note that certainty remains low when evaluating specific critical outcomes such as all-cause mortality or the progression of established Rheumatic Heart Disease (RHD).

For Serious Systemic Infections like sepsis and meningitis, research includes RCTs where Despacilina is often used as a comparison agent, alongside specialized Pharmacokinetic (PK) studies. PK studies show that drug concentration levels may fluctuate significantly in critically ill adults and neonates, leading to ongoing research to address how standard schedules affect drug levels.

Research into Special Populations includes studies in pregnant women with Syphilis, where its research findings are referenced in regulatory guidelines concerning congenital infection. Overall, research gaps are acknowledged across the evidence base, with certainty remaining low for long-term survival outcomes and a continued need to determine the most effective dosing strategies for critically ill and vulnerable patient groups.

Frequently Asked Questions (FAQ)

Common questions about Despacilina (FAQ)


Q: I heard Despacilina is similar to Drug X; how are they different?

A: Official documents describe Despacilina (Benzylpenicillin) as having different salt forms, such as the short-acting type and the long-acting Benzathine salt. These different forms are noted to have different clinical uses and require separate administration procedures. The specific formulation determines its therapeutic use and how it is administered.


Q: Is it normal to feel a bit nauseous when starting Despacilina?

A: Official regulatory documents list nausea among the possible side effects of Despacilina. Other common gastrointestinal disturbances reported in official product information include vomiting and diarrhea.


Q: What types of side effects are generally considered mild and temporary with Despacilina?

A: Regulatory labels classify effects like skin rashes, hives (urticaria), and reactions at the injection site (pain, inflammation) as common. These common effects are distinct from rare, serious risks like anaphylaxis (a severe allergic reaction) or seizures.


Q: Why is Despacilina sometimes given for conditions other than its main use?

A: Despacilina has multiple approved indications (uses) listed in official sources, not just one. For example, in addition to treating serious systemic infections, regulatory documents confirm its use for conditions like strep throat, diphtheria, syphilis, yaws, and the prevention of rheumatic fever recurrence.


Q: Does taking Despacilina with food make a difference?

A: Official product information confirms that Despacilina is administered only by injection, either into a muscle (intramuscular) or a vein (intravenous). Since it is not a medicine taken by mouth, there is no interaction with food.


Q: Is it common for people to need a dosage adjustment for Despacilina?

A: Dosage adjustments are documented as necessary only for specific patient populations. For instance, regulatory labeling requires dose adjustment for people with severe renal impairment (reduced kidney function) to prevent the drug from accumulating in the body and potentially causing neurotoxicity.


Q: Is Despacilina safe to use for older adults?

A: Regulatory information notes that delayed drug clearance is observed in the elderly population due to naturally reduced kidney function, which requires caution when the medicine is used in this age group.


Q: Is it true that Despacilina can cause dizziness?

A: Dizziness is listed in the official product information as one of the possible side effects. Other common complaints noted alongside dizziness include headache and nausea.


Q: Are there different strengths of Despacilina?

A: Yes, official labeling confirms the existence of different strengths. The quantity of the drug is indicated using both mass (such as milligrams or grams) and specific units of activity, known as International Units (IU).


Q: Does taking Despacilina affect birth control pills?

A: Official drug information indicates that penicillin G injection may decrease the effectiveness of hormonal contraceptives. This includes birth control pills, patches, rings, and injections.


Q: Is Despacilina generally well-tolerated?

A: Official summaries often state that the drug is overall well-tolerated by most people. However, regulatory documents consistently note that pain at the injection site is a very common concern associated with the parenteral (injection) administration route.


Q: Can Despacilina affect my ability to drive?

A: Official documentation states that the medicine generally does not cause problems with the ability to drive. However, side effects like dizziness, drowsiness, and tiredness are documented, and these may affect an individual's ability in some cases.


Q: Is there a known link between Despacilina and mood changes?

A: The Nervous System section in regulatory labeling lists adverse reactions such as nervousness, confusion, anxiety, and euphoria. These are generally considered serious and may reflect changes in the central nervous system.


Q: How long does Despacilina stay in the body after the last use?

A: Pharmacokinetic data shows that the elimination half-life for short-acting forms of Penicillin G is approximately 1.4 hours or less. It is estimated that the drug is typically cleared from the system in about 7.7 hours (roughly 5.5 times the half-life).


Q: Does Despacilina lose effectiveness over time?

A: Studies cited in authoritative sources show that the drug in solution can degrade when it is diluted and stored, even under refrigeration. This potential degradation over time is noted to reduce the medicine's potency.


Q: What age group is Despacilina usually prescribed for?

A: While Despacilina is approved for use across all age groups—including adults, adolescents, children, and neonates—it is specifically noted in clinical literature for its use in treating serious conditions like neonatal sepsis (infection in newborns) and various infections in older individuals.


Q: Why is Despacilina sometimes described as a 'first-line' treatment?

A: Natural penicillins like Despacilina are described in the literature as the standard treatment for several infections caused by susceptible organisms. This designation is generally based on the drug being considered the standard treatment for several infections caused by susceptible organisms, such as Streptococcus groups.


Q: What are the current regulatory classifications for Despacilina?

A: Despacilina is officially classified in regulatory databases as a β-Lactam Antibiotic, specifically a Natural Penicillin. It is further classified as a Prescription-Only medication.

How should Despacilina be stored and disposed of?

Official Storage Requirements

Despacilina (Benzylpenicillin/Penicillin G) must be stored strictly according to its official labeling to maintain stability. The product requires storage at controlled room temperature, typically 20 C to 25 C, and must not be frozen. It is mandatory to keep the medicine in its original container and outer carton to protect it from light and moisture. Furthermore, the container must be kept tightly closed until use.

Stability and Child Safety

Once the sterile powder is prepared for injection (reconstituted), the resulting solution has a limited stability period and must be used immediately or within a short, specified timeframe, as detailed in the prescribing information. Always keep Despacilina out of the sight and reach of children.

Disposal Instructions

Unused medicinal product and waste material must be disposed of in accordance with local regulatory requirements for pharmaceutical waste. To prevent environmental exposure to antibiotics, it must not be poured into wastewater or disposed of via household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Despacilina found in:

A-Z Index: